Bone Biologics Corp (BBLG): Price and Financial Metrics
GET POWR RATINGS... FREE!
BBLG Stock Price Chart Interactive Chart >
BBLG Price/Volume Stats
| Current price | $0.29 | 52-week high | $6.78 |
| Prev. close | $0.30 | 52-week low | $0.25 |
| Day low | $0.27 | Volume | 11,625 |
| Day high | $0.29 | Avg. volume | 491,522 |
| 50-day MA | $0.56 | Dividend yield | N/A |
| 200-day MA | $1.43 | Market Cap | 2.96M |
Bone Biologics Corp (BBLG) Company Bio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Latest BBLG News From Around the Web
Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.
BBLG: A Potential Game-Changer for Back SurgeriesBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a medical device company focused on addressing the spinal fusion market with their worldwide exclusive use of the NELL-1 technology developed by the UCLA Technology Development Group (UCLA TDG). NELL-1 has shown in clinical studies involving rats the ability to stimulate bone growth in a more |
Bone Biologics CEO Issues Letter to StockholdersBURLINGTON, Mass., October 25, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick. |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Roche Holding AG (OtherRHHVF) and Bone Biologics (BBLG)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGX – Research Report), Roche Holding AG (RHHVF – Research Report) and Bone Biologics (BBLG – Research Report). Argenx Se (ARGX) Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se today and set a price target of $469.00. The company's shares closed last Monday at $361.05. According to TipRanks. |
WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public OfferingWallachBeth Capital LLC, a leading provider of capital markets and institutional execution services announced yesterday the closing of Bone Biologics (NASDAQ: BBLG) previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. |
Bone Biologics Announces Closing of $5,100,000 Underwritten Public OfferingBURLINGTON, Mass., October 12, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company plans to use the net proceeds to fund its planned clinical trials, maintain and extend its patent por |
BBLG Price Returns
| 1-mo | -27.50% |
| 3-mo | -76.61% |
| 6-mo | -81.53% |
| 1-year | -92.43% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -91.76% |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...